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Lipoxygenase metabolites of arachidonic acid can act as growth promoting factors for various cancer cell lines. Here we
demonstrate that the 5-lipoxygenase inhibitor nordihydroguaiaretic acid potently inhibits anchorage-independent growth of
human pancreatic and cervical cancer cells in soft agar and delays growth of pancreatic and cervical tumours established in
athymic mice. Furthermore, nordihydroguaiaretic acid induces apoptosis of these cancer cells in vitro and in vivo. Potential
mechanisms mediating these effects of nordihydroguaiaretic acid were examined. Nordihydroguaiaretic acid had no inhibitory
effect on growth and survival signals such as tyrosine phosphorylation of the epidermal growth factor receptor or basal and
growth factor-stimulated activities of extracellular signal-regulated kinase 1/2, p70
s6k and AKT but selectively inhibited
expression of cyclin D1 in the cancer cells. In addition, treatment with nordihydroguaiaretic acid lead to a disruption of the
ﬁlamentous actin cytoskeleton in human pancreatic and cervical cancer cells which was accompanied by the activation of Jun-
NH2-terminal kinase and p38
mapk. Similar effects were obtained by treatment of the cancer cells with cytochalasin D. These
results suggest that nordihydroguaiaretic acid induces anoikis-like apoptosis as a result of disruption of the actin cytoskeleton in
association with the activation of stress activated protein kinases. In conclusion, nordihydroguaiaretic acid could constitute a
lead compound in the development of novel therapeutic agents for various types of cancer.
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Arachidonic acid and its metabolites are important second messen-
gers in the signal transduction pathways induced by receptor
tyrosine kinases and G protein coupled receptors (Di Marzo,
1995; Rozengurt, 1998). 5-hydrocicosatetraenoic acid (5-HETE),
the major 5-lipoxygenase metabolite of arachidonic acid, has been
implicated as a growth promoting factor for various human cancer
cells including prostate, lung and pancreatic cancer cells (Avis et al,
1996; Ghosh and Myers, 1998; Ding et al, 1999a). The resinous
plant exudate nordihydroguaiaretic acid (NDGA) inhibits lipoxy-
genases including 5-lipoxygenases (Van Wauwe and Goossens,
1983; Chang et al, 1984). Although nordihydroguaiaretic acid
(NDGA) may target other kinases (Rondeau et al, 1990; Domin
et al, 1993), it has been used extensively to examine the role of
the lipoxygenase pathway in the action of growth factors and cyto-
kines (Haliday et al, 1991; Peppelenbosch et al, 1992). Indeed,
NDGA blocks lipoxygenase production, inhibits growth and
induces apoptosis of human lung cancer cells (Avis et al, 1996;
Ghosh and Myers, 1998). In pancreatic cancer cells, NDGA inhibits
thymidine incorporation and anchorage-dependent proliferation
and induces apoptosis in vitro (Ding et al, 1999a,b). However,
the potential mechanisms mediating these effects have not been
examined. In addition, it is still unclear whether NDGA can block
growth of various tumours in vivo. This is an important question
as numerous compounds inhibit cancer cell growth in vitro but fail
to be effective in vivo.
Apoptosis can be induced by many different events such as
direct damage to the cell or its DNA or by the removal of survival
signals provided by growth factors, cell–cell contacts and the
extracellular matrix. The Raf-MEK-ERK cascade is one of the
major signalling pathways promoting cell survival (Parrizas et al,
1997; Kurada and White, 1998; Anderson and Tolkovsky, 1999;
Bonni et al, 1999). However, Ras-dependent cell survival is likely
to require additional downstream effectors such as the PI3-
kinase-AKT signaling pathway (Datta et al, 1999). There is a
controversy regarding the contribution of other mitogen-activated
protein kinases (MAPKs) such as Jun-NH2 terminal kinase (JNKs)
and p38
mapk to cell survival or apoptosis. Under certain circum-
stances, activation of JNKs contributes to proliferation. However,
in other model systems, activation of JNKs and p38
mapk (also
known as stress activated protein kinases) can mediate apoptosis
(Xia et al, 1995; Chen et al, 1996; Verheij, 1996; Zanke et al,
1996; Bossy-Wetzel et al, 1997; Behrens et al, 1999; Tournier et
al, 2000). A similar role for stress activated protein kinases has
been proposed for anoikis, the induction of apoptosis in epithelial
cells by disruption of cell-cell and cell-matrix contacts (Frisch and
Francis, 1994; Frisch et al, 1996).
Here we demonstrate that NDGA markedly inhibits growth and
induces apoptosis of human pancreatic and cervical cancer cells in
vitro and in vivo. NDGA did not prevent constitutive phosphoryla-
tion of p70
s6k in these cells which regulates autonomous
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www.bjcancer.comanchorage-dependent and -independent proliferation of tumour
cells (Grewe et al, 1999). In addition, NDGA did not inhibit major
survival pathways such as tyrosine phosphorylation of the EGFR,
or TGFa-induced activation of the ERK cascade and AKT.
However, treatment of cells with NDGA leads to activation of JNKs
and p38
mapk, disruption of the ﬁlamentous actin cytoskeleton and
cell detachment in a sequential fashion. Similar results were
observed using cytochalasin D. These results provide novel infor-
mation about the potential mechanisms of action of NDGA in
human pancreatic and cervical cancer cells and suggest that this
agent may provide a lead compound for new therapies against both
cancers.
MATERIALS AND METHODS
Cell culture
Human SW 850 pancreatic (Muller et al, 1998; Taniguchi et al,
1998) and C4-I cervical cancer cells were the kind gift of W
Schmiegel, Department of Internal Medicine, Medical University
of Bochum, Germany. Stocks were maintained in RPMI medium
supplemented with 10% (v/v) FBS in a humidiﬁed atmosphere of
5% CO2:95% air at 378C. They were passaged every 3 days.
Clonogenic Assay
SW 850 and C4-I cells were washed, trypsinised and resuspended
in RPMI. Cells were then disaggregated by two passes through a
19-gauge needle into an essentially single cell suspension as judged
by microscopy. Cell number was determined using a cell counting
chamber and 2610
4 cells were mixed with RPMI/0.5% or 10%
FBS containing 0.3% agarose in the presence or absence of NDGA
at the concentrations indicated, and layered over a solid base of
0.5% agarose in RPMI/0.5% or 10% FBS in the presence or
absence of NDGA at the same concentrations in 33 mm dishes.
The cultures were incubated in humidiﬁed 5% CO2:95% air at
378C for 14 days and then stained with the vital stain nitro-blue
tetrazolium. Colonies of 4120 mm in diameter (25 cells) were
counted using a microscope.
Immunoprecipitations and Western blotting
SW 850 and C4-I cells were washed twice in serum-free RPMI and
incubated in fresh RPMI for further 24 h. Cells were then treated
with NDGA as indicated in the ﬁgure legends and lysed in
50 mM Tris-HCl, 5 mM EDTA, 100 mM NaCl, 40 mM b-glycero-
phosphate, 50 mM NaF, 1 mM Na3VO4, 1% Triton X-100, 1 mM
phenylmethylsulphonyl ﬂuoride, 10 mgm l
71 aprotinin, 10 mg
ml
71 leupeptin (pH 7.6, lysis buffer). For immunoprecipitations,
lysates were incubated with a polyclonal anti-EGF-receptor anti-
body for 2 h at 48C on a rotating wheel with protein A
sepharose beads added for the second hour. Beads were washed
twice in lysis buffer and resuspended in 26 SDS–PAGE sample
buffer. Proteins were further analysed by SDS–PAGE followed by
Western blotting using a monoclonal anti-Tyr(P) antibody with
immunoreactive bands being visualised by enhanced chemolumi-
nescence detection. For detection of cyclin D1, cyclin E, p27
kip1
and p38 phosphorylated at Thr
180 and Tyr
182 and AKT phosphory-
lated at Thr
308 cells were treated as indicated in the ﬁgure legends,
lysed in SDS–PAGE sample buffer and samples were further
analysed by SDS–PAGE and Western blotting with speciﬁc anti-
sera to these proteins essentially as described above.
Kinase assays
For ERK assays serum-starved SW 850 and C4-I cells were incu-
bated with TGFa or NDGA in the presence or absence of 15 mM
PD 098059 as indicated in the ﬁgure legends. Controls received
an equivalent amount of solvent. Cells were then lysed at 48Ci n
1 ml RIPA buffer (150 mM NaCl, 1% NP-40, 1% DOC, 0.1%
SDS, 50 mM Tris, pH 7.4, 2 mgm l
71 aprotinin, 40 mgm l
71 besta-
tin, 0.5 mgm l
71 leupeptin, 0.5 mM AEBSF, 0.7 mgm l
71
pepstatin). Immunoprecipitations were performed at 48C using
an anti-ERK1/2 antibody for 2 h with protein A agarose added
for the second hour. Immune complexes were washed three times
in lysis buffer and once with ERK kinase buffer (15 mM MgCl2,
15 mM Tris-HCl, pH 7.4). Kinase reactions were performed by
resuspending the protein A sepharose pellets in 25 ml of kinase
assay mixture containing the appropriate kinase buffer with
0.2 mM MBP, 20 mM ATP, 5 mCi ml
71 [g-
32P]ATP, 2 mM cAMP-
dependent protein kinase inhibitor peptide and 100 nM microcys-
tin LR. Incubations were performed under linear assay conditions
at 308C for 20 min and terminated by adding 20 mlo f5 6SDS-
sample buffer. Samples were boiled for 10 min at 958C and
proteins were separated by SDS–PAGE followed by autoradiogra-
phy. For JNK and p38
mapk cells were washed with PBS and lysed in
20 mM HEPES pH 7.4, 2 mM EGTA, 50 mM b-glycerophosphate,
1m M DTT, 1 mM Na3VO4, 10% glycerol, 1% Triton X-100,
2 mM leupeptin, 0.5 mM AEBSF, 5 mgm l
71 aprotinin, 0.1 mgm l
71
okadaic acid. After 5 min on ice, the lysate was clariﬁed and
immunoprecipitated with the respective antibodies. The immuno-
precipitates were washed thrice each in lysis buffer and ﬁnally in
assay buffer (JNK: 20 mM MOPS pH 7.2, 2 mM EGTA, 10 mM
MgCl2, 1 mM DTT, 0.1% Triton X-100; p38: 20 mM MOPS,
pH 7, 1 mM EDTA, 5% glycerol, 0.1% b-mercaptoethanol, 0.01%
Brij 35, 0.1 mgm l
71 okadaic acid). Kinase reactions contained
20 ml kinase buffer with 1 mg of either ATF2- or cJun-GST fusion
protein and Mg-ATP mixes as follows: JNK, 7.5 ml5 0m M MgCl2,
100 mM ATP, 2 mCi [g-
32P]ATP; p38
mapk,6ml6 0m M Mg acetate,
300 mM ATP and 2 mCi [g-
32P]ATP. After 20 min at 308C, the
reactions were stopped by addition of 56SDS–PAGE sample
buffer and further analysed as described above. GST-cJun and
GST-ATF2 fusion proteins were prepared essentially as described
(Seufferlein et al, 1999).
p70
s6k mobility shift assays
Activation of p70
s6k by mitogens can be determined by the appear-
ance of slower migrating forms in SDS–PAGE due to
phosphorylation of p70
s6k on Thr
229 and Thr
389 and Ser
404 which
are not phosphorylated in quiescent cells (Ferrari and Thomas,
1994). For p70
s6k mobility shift assays cells were treated as indi-
cated in the ﬁgure legends and lysed in SDS–PAGE sample
buffer. Samples were further analysed by SDS–PAGE and Western
blotting with a speciﬁc anti-p70
s6k antibody.
In situ detection of apoptotic cells
DNA fragmentation was measured by catalytically incorporating
ﬂuorescein-12-dUTP at the 3'-OH DNA ends using the enzyme
TdT according to the principle of the TUNEL assay. To detect
apoptosis in tumour xenografts parafﬁn-embedded tissue sections
of the tumours were deparafﬁnised and rehydrated through graded
ethanol washes, ﬁxed in 4% methanol-free formaldehyde, treated
with 20 mgm l
71 proteinase K solution for 8–10 min, ﬁxed again
and further processed according to the manufacturer’s protocol.
Tumour growth in athymic mice
1.5610
6 SW 850 or 2610
6 C4-I cells were inoculated subcuta-
neously into both ﬂanks of 4–6 week old female athymic NMRI/
nu-nu mice and the mice were maintained in a pathogen-free
environment. The animals were observed daily for tumour develop-
ment. When measurable tumours were established (415 mm
3), the
animals were randomised into two groups of six animals. One
group received 750 mg NDGA (corresponding to about 90 mM
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1188–1196NDGA (w/v)) in 0.1 ml of a solution containing 90% sterile H2O
and 10% ethanol i.p. 56 per week. The control animals received
an equivalent amount of solvent i.p. Tumour size was measured
twice weekly and mice were killed after 3 weeks of treatment.
Growth curves for xenografts were determined by externally
measuring the length, height and width of the tumours, and
the volume was calculated according to the following equation:
volume=(length6height6width)60.5. To examine statistical
signiﬁcance an univariate Students t-test was performed.
Materials
NDGA was obtained from FLUKA/Sigma-Aldrich (Deisenhofen,
Germany). Antibodies against p70
s6k, p27
kip1, cyclin D1, cyclin E,
JNK1/2, p38
mapk, and the EGFR were obtained from Santa Cruz
Biotechnology (Santa Cruz, USA). The phospho-speciﬁc anti-
p38
mapk and anti-AKT antibodies were from New England Biolabs
(Schwalbach/Taunus, Germany). Protein A sepharose was obtained
from Boehringer Mannheim (Mannheim, Germany). ECL-reagent
and [g-
32P]-ATP were obtained from Amersham/Pharmacia (Frei-
burg, Germany). The apoptosis detection system ﬂuorescein was
from Promega (Mannheim, Germany). Oregon-green labelled phal-
loidin was obtained from Molecular Probes (Leiden, Netherlands).
MBP was from Sigma (Deisenhofen, Germany). All other reagents
were of the purest grade available.
RESULTS
NDGA delays growth of tumours established in athymic
mice
To establish whether NDGA could indeed inhibit tumour growth
in vivo we ﬁrst examined a panel of various epithelial cancer cell
lines for their ability to consistently induce xenograft tumours in
nude mice. Among these tumour cell lines, SW 850 human
pancreatic cancer cells and C4-I human cervical cancer cells
induced tumour xenografts in athymic mice most consistently
and were therefore used for all subsequent experiments (data not
shown). Tumours were established by subcutaneous injection of
SW 850 and C4-I cells to both ﬂanks of athymic mice. When
the tumour volume was 15 mm
3, mice were treated with ﬁve times
per week i.p. injections of NDGA or diluent for 3 weeks. As shown
in Figure 1A, treatment with NDGA delayed the growth of both
SW 850 and C4-I tumours by about 50%. The compound was very
well tolerated by the animals. No side effects or behavioural
abnormalities were observed during the course of treatment. There
were no marked differences in body weight of the animals treated
with NDGA or with solvent during the course of treatment despite
the fact that the animals treated with solvent had bigger tumours.
In animals injected with SW 850 cells, body weight in the control
group was 21.5+1.8 g at the beginning and 24+1.3 g at the end of
the treatment. In the NDGA group body weight of the animals was
23.3+1.2 g at the beginning and 24.3+1.4 g at the end of the
treatment. The corresponding ﬁgures in the animals injected with
C4-I cells were 27.5+2.1 g and 29.8+1.7 g in the control group
and 27.5+2 g and 29.2+2.1 g in the NDGA group, respectively.
NDGA inhibits anchorage-independent growth of SW 850
and C4-I cancer cells
In addition to its effect on tumour growth in vivo we examined the
effect of NDGA on colony formation of SW 850 and C4-I cells in
soft agar, a useful in vitro-test to judge the efﬁcacy of a compound
as a potential anticancer agent (Carney et al, 1980). NDGA
potently inhibited colony formation in response to both 0.5%
FBS and 10% FBS, which induced maximum clonogenic growth
in SW 850 and C4-I cells (Figure 1B). Thus, NDGA is a potent
inhibitor of anchorage-independent growth in SW 850 and C4-I
cells even in the presence of maximum stimulatory concentrations
of FBS.
NDGA has previously been reported to inhibit thymidine incor-
poration and anchorage-dependent proliferation in human
pancreatic cancer cells (Ding et al, 1999a). We conﬁrmed these
observations in SW 850 and also in C4-I cervical cancer cells (data
not shown). Interestingly, we observed that as early as 8 h after
treatment with NDGA, cells started to detach from the tissue
culture dishes making it difﬁcult to determine whether the reduc-
tion in thymidine incorporation and cell numbers observed in
response to NDGA were due to inhibition of DNA synthesis rather
than cell detachment.
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Figure 1 (A) NDGA delays growth of xenograft tumours established in
athymic mice A: 1.5610
6 SW 850 or 2610
6 C4-I cells were inoculated
subcutaneously into both ﬂanks of 4–6 week old female athymic NMRI/
nu-nu mice and the mice were maintained in a pathogen-free environment.
When measurable tumours were established (415 mm
3), the animals
were randomised into two groups of six animals and treated as described
in Materials and Methods. Growth curves for xenografts were determined
by externally measuring the length, height and width of the tumours at the
days indicated. The tumour volume was calculated according to the follow-
ing equation: volume=(length6height6width)60.5. Values are the means
+SE (n=6). Mice were sacriﬁced after 3 weeks of treatment with 750 mg
NDGA 56 per week i.p. * Indicates a statistically signiﬁcant difference in
tumour size between the NDGA group and the control group
(P50.05). (B) NDGA inhibits colony growth in SW 850 and C4-I cells.
(A) Single cell suspensions of SW 850 (left panel), or C4-I cells (right panel)
were plated at a density of 3610
4 cells/dish in agarose medium containing
RPMI and 0.5% (left) or 10% FBS (right) and various concentrations of
NDGA as indicated. Colonies were counted after 2 weeks of incubation.
In all cases, a representative of two independent experiments each per-
formed in triplicates is shown.
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NDGA has been reported to induce apoptosis in certain cancer
cells in vitro. Indeed, NDGA induced apoptosis in SW 850 pancrea-
tic cancer cells and also in C4-I human cervical cancer cells as
judged by TUNEL assays (Figure 2A). Upon treatment of cells with
25 mM NDGA for 12 h, the proportion of cells exhibiting fragmen-
ted DNA markedly increased from 2 to 34% in SW 850 and from 0
to 26% in C4-I cells. The apoptosis-inducing effect of NDGA was
ﬁrst detectable after 3 h of incubation and reached a maximum
after 12–16 h of incubation (data not shown). To examine
whether NDGA induced similar molecular mechanisms in the
pancreatic and cervical xenograft tumours in vivo, parafﬁn-
embedded tissue sections of tumours obtained from animals trea-
ted with NDGA or with solvent were examined by in situ-
ﬂuorescence TUNEL assays. Treatment of mice with NDGA led
to a marked increase in the number of apoptotic cells in tumours
established from SW 850 and C4-I cells (Figure 2B). Thus, NDGA
induces apoptosis in pancreatic and cervical tumours in vitro and
in vivo.
NDGA does not inhibit growth and survival signals in SW
850 and C4-I cells
Next, we were interested in potential mechanisms mediating the
growth inhibitory effect of NDGA in human pancreatic and cervi-
cal cancer cells. NDGA has been shown to inhibit tyrosine
phosphorylation of certain receptor tyrosine kinases (Domin et
al, 1993). The EGFR and its respective ligands such as TGFa trigger
growth and prevent apoptosis by autocrine and/or paracrine
mechanisms in many cancer cell lines (Korc et al, 1992; Bonni et
al, 1999; Seufferlein et al, 1999). To examine whether NDGA could
inhibit tyrosine phosphorylation of the EGFR, serum starved SW
850 and C4-I cells were treated with TGFa in the absence or
presence of NDGA and autophosphorylation of the EGFR was
determined by anti-Tyr(P) Western blotting. NDGA had no effect
on TGFa-induced tyrosine phosphorylation of the EGFR in SW
850 and C4-I cells, respectively (Figure 3A). Similar data were
obtained for insulin-like growth factor I-induced phosphorylation
of the IGF-I receptor (data not shown).
Activity of the serine-threonine kinase p70
s6k is important for
progression from the G1 to the S phase of the cell cycle (Chou
and Blenis, 1995). We have recently demonstrated that the
FRAP-p70
s6K pathway is constitutively active in human pancreatic
cancer cells and regulates autonomous growth of these cells (Grewe
et al, 1999). As shown in Figure 3B, NDGA did not substantially
inhibit basal phosphorylation of p70
s6k. NDGA treatment of SW
850 cells also did not markedly interfere with further phosphoryla-
tion of p70
s6k in response to TGFa. In contrast, treatment of cells
with the selective inhibitor of the FRAP-p70
s6k pathway, rapamycin
(Brown et al, 1995), prevented both, basal and TGFa-stimulated
phosphorylation of p70
s6k (Figure 3B). Similar results were
obtained in the C4-I cell line (data not shown).
Ras activates two major survival pathways, the ERK cascade and
AKT (Anderson and Tolkovsky, 1999; Bonni et al, 1999; Datta et
al, 1999). NDGA did not inhibit phosphorylation of the antiapop-
totic protein kinase AKT in TGFa-stimulated C4-I cells. In
contrast, inhibition of the major upstream regulator of AKT,
PI3-kinase, by the selective PI3-kinase inhibitor LY294002 mark-
edly prevented TGFa-stimulated AKT phosphorylation in C4-I
cells (Figure 3C). Similar data were obtained in SW 850 cells (data
not shown). NDGA had also no effect on basal and TGFa-stimu-
lated activation of ERK1/2. In contrast, the selective MEK-1
inhibitor PD 098059 inhibited both basal and TGFa-stimulated
activation of ERK1/2 (Figure 3D). These data demonstrate that
NDGA does not act as an inhibitor of the EGFR kinase or the acti-
vation of the Ras/Raf/ERK- or the Ras/PI3-kinase/AKT/p70
s6k
signalling pathways in pancreatic and cervical cancer cells.
NDGA inhibits expression of cyclin D1 in SW 850 and C4-I
human cancer cells
Thus, inhibition of tumour cell growth by NDGA could not be
explained by inhibition of the major growth promoting intracellu-
lar signalling pathways in response to NDGA. Therefore, we
reasoned that this compound could directly affect the regulation
of the cell cycle machinery. In particular, cyclin D1 is a major regu-
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Figure 2 NDGA induces apoptosis in SW 850 and C4-I cells in vitro and
in vivo.( A) Upper panels: SW 850 (left) and C4-I cells were incubated with
25 mM NDGA for 18 h and DNA fragmentation was determined by in situ-
ﬂuorescence TUNEL assays as described in Materials and Methods. Lower
panels: The proportion of TUNEL positive cells was counted in four inde-
pendent microscopic ﬁelds (N= NDGA). (B) Parafﬁn sections of tumour
xenografts (left SW 850, right C4-I) obtained from mice treated with
NDGA (NDGA) or solvent (7) were analysed by an in situ-ﬂuorescence
TUNEL assay to detect DNA fragmentation as described in Materials and
Methods. Apoptotic cells are characterised by a strong ﬂuorescence within
the nucleus corresponding to labelling of fragmented DNA.
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is overexpressed in many cancers (Weinstein, 1996). In pancreatic
cancer, overexpression of cyclin D1 is associated with increased
aggressiveness of these tumours (Kornmann et al, 1998). We have
previously shown that cyclin D1 and E but also cyclin-dependent
kinase inhibitors such as p27
kip1 are constitutively expressed in
human pancreatic cancer cells (Grewe et al, 1999). As shown in
Figure 3E, cyclin D1, cyclin E and p27
kip1 were also constitutively
expressed in C4-I human cervical cancer cells. Incubation of cells
with NDGA resulted in a marked reduction in the expression of
cyclin D1 in both cell lines whereas the levels of expression of
cyclin E and p27
kip1 remained unchanged. These results suggest
that the inhibition of proliferation in response to NDGA in SW
850 and C4-I cells could, at least in part, be mediated by inhibition
of cyclin D1 expression.
NDGA and cytochalasin D induce depolymerisation of the
actin cytoskeleton in SW 850 and C4-I cells
The actin cytoskeleton in concert with adhesion molecules controls
cell-cell and cell-substrate interactions and participates in trans-
membrane signalling. Upon treatment of cells with NDGA we
observed substantial cell detachment. This could be a consequence
of the induction of apoptosis, but also due to a more direct effect
of NDGA on the cytoskeleton in pancreatic and cervical cancer
cells. To examine the effect of NDGA on the actin cytoskeleton
in SW 850 and C4-I cells, actin was analysed by immunoﬂuores-
cence using Oregon-green-labelled phalloidin after treatment of
cells with NDGA or solvent. As shown in Figure 4 (top panels),
control cells exhibited a well developed actin cytoskeleton with a
circumferential actin ﬁlament network, actin microspikes at the
plasma membrane and actin stress ﬁbres crossing the cells. Strik-
ingly, within 30 min of exposure to 25 mM NDGA, actin stress
ﬁbers disappeared and the number of mikrospikes was markedly
reduced. A maximum effect of NDGA on the actin cytoskeleton
was observed after 60 min of incubation (Figure 4, middle panels)
and clearly preceded cell detachment and the induction of apopto-
sis in response to NDGA (data not shown). Interestingly, cortical
actin ﬁlaments were less affected by the NDGA treatment (Figure
4, middle panels). The effect of NDGA on the ﬁlamentous actin
cytoskeleton was comparable to that of cytochalasin D. However,
in addition to the disruption of actin stress ﬁbres, cytochalasin D
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Figure 3 (A) TGFa-induced tyrosine phosphorylation of the EGFR in
SW 850 and C4-I cells is not affected by NDGA treatment of cells. Serum
starved SW 850 (left) or C4-I cells (right) were treated for 60 min with
25 mM NDGA (+). Control cells received an equivalent amount of solvent
(7). Cells were subsequently treated with 50 ng ml
71 TGFa (TGFa,+ )o r
an equivalent amount of solvent (7) for 10 min. Cells were then lysed and
tyrosine phosphorylation of the EGFR was further analysed as described in
Materials and Methods. (B) NDGA does not inhibit constitutive and TGFa-
stimulated phosphorylation of p70
s6k in SW 850 cells. Serum-starved cul-
tures of SW 850 cells were treated for 15 min with 50 ng ml
71 TGFa
in the absence (7) or presence of 30 mM NDGA (NDGA, +) or
20 ng ml
71 rapamycin (Rapa, +) or received an equivalent amount of sol-
vent (7). p70
s6k mobility shift assays were performed as described in Ma-
terials and Methods. The results shown in each case are representative of
three independent experiments. The positions of hypophosphorylated
p70
s6k (p70
s6k) and the slower migrating phosphorylated p70
s6k (pp70
s6k)
are indicated by arrows. (C) NDGA does not inhibit basal and TGFa-sti-
mulated activation of AKT. Serum-starved cultures of C4-I cells were trea-
ted for 15 min with 50 ng ml
71 TGFa in the absence (7) or presence of
30 mM NDGA (+) or 20 mM LY294002 (+) or received an equivalent
amount of solvent (7). Phosphorylation of AKT at Ser
431 was determined
using an activation-speciﬁc antibody as described in Materials and Methods
and is indicated by an arrow (AKT
Ser431). The same samples were also ana-
lysed using a pan-AKT antibody. The position of AKT is indicated by an ar-
row. (D) NDGA does not inhibit basal and TGFa-stimulated activation of
ERK1/2: Serum-starved cultures of C4-I cells were treated for 15 min with
50 ng ml
71 TGFa (T) in the absence (7) or presence of 25 mM NDGA
(N) or 15 mM PD 098059 (PD) or received an equivalent amount of sol-
vent (7). ERK1/2 immune complex kinase assays were performed as de-
scribed in Materials and Methods. (E) NDGA inhibits constitutive cyclin D1
expression in SW 850 and C4-I cancer cells: Subconﬂuent cultures of SW
850 and C4-I cells were treated with 25 mM NDGA (N) for 18 h. Control
cells received an equivalent amount of solvent (7). Cells were lysed and
further analysed by Western blotting with either anti-cyclin D1, anti-cyclin
E or anti-p27
kip1 antibodies as indicated by an arrow. The results shown in
each case are representative of at least three independent experiments.
SW 850 C4-1
—
NDGA
Cyto D
Figure 4 NDGA and cytochalasin D induce breakdown of the actin cy-
toskeleton. Serum starved SW 850 (left) and C4-I cells (right) were treated
with 25 mM NDGA (NDGA) or 2 mM cytochalasin D (Cyto D) for 60 min
or received an equivalent amount of solvent (7). Cells were subsequently
ﬁxed and actin was further analysed by immunocytochemistry as described
in Materials and Methods.
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bottom panels). The effect of cytochalasin D on the actin
cytoskeleton in SW 850 and C4-I cells was ﬁrst visible at 0.3 mM
and reached a maximum at 2 mM cytochalasin D. At these concen-
trations, cytochalasin D also induced apoptosis in both cell lines
(data not shown). These data suggest that NDGA by inhibiting
the organisation of actin stress ﬁbers in SW 850 and C4-I cells
interferes with cell-matrix interaction and induces anoikis.
NDGA and cytochalasin D activate stress-activated protein
kinases in SW 850 and C4-I cells
Anoikis by detachment of epithelial cells from their matrix is asso-
ciated with the activation of Jun-NH2-terminal kinases (Frisch et
al, 1996). Treatment of SW 850 and C4-I cells with cytochalasin
D also induced JNK1/2 activation in a concentration dependent
manner reaching a maximum at 2.4 mM cytochalasin D in both cell
lines (Figure 5A and data not shown). Interestingly, NDGA also
induced a dose dependent activation of JNK1/2 in both cell lines
with a maximum effect at 25 mM (Figure 5B, top panel and data
not shown). In both cell lines, GST-cJun phosphorylation in
response to NDGA was about 60% of that in response to 1 mM
mannitol, a potent osmotic stressor (Kyriakis and Avruch, 1996)
(Figure 5B, bottom panels). Furthermore, NDGA induced phos-
pho-JNK immunoreactivity exclusively in the nucleus of SW 850
and C4-I cells treated with NDGA providing additional evidence
that NDGA is a strong activator of JNKs (Cavigelli et al, 1995;
Sanchez-Perez et al, 1998; data not shown).
Figure 5C shows the kinetics of NDGA-induced JNK1/2 activa-
tion. Activation of JNK1/2 in response to NDGA was detectable as
early as 10 min following treatment of SW 850 and C4-I cells with
25 mM NDGA; a maximum effect was obtained after 60 min of
incubation.
NDGA did not affect the activation of the non-stress related
members of the MAPK family ERK1/2 in cancer cell lines exam-
ined. In marked contrast, the results in Figure 6A demonstrate
that NDGA activates the stress related p38
mapk in immune complex
kinase assays reaching 60 and 50% of mannitol-induced GST-ATF2
phosphorylation in SW 850 and C4-I cells, respectively. Activation
of p38
mapk occurs upon dual phosphorylation at Thr
180 and Tyr
182
(Han et al, 1994). Using an antibody which speciﬁcally detects
phosphorylation of the kinase at these two residues, p38
mapk phos-
phorylation was ﬁrst detectable at about 2 mM NDGA reaching a
maximum at 15 mM NDGA in C4-I and SW 850 cells (Figure 6B,
top panel and data not shown). p38
mapk phosphorylation could
be detected as early as 5 min after incubation with NDGA reaching
a maximum after 30 min of incubation (Figure 6B, bottom panel
and data not shown). Thus, NDGA selectively activates the
stress-activated protein kinases of the MAPK family.
DISCUSSION
A better understanding of the biology of tumours could greatly
improve our current concepts of cancer therapy. Arachadonic acid
and its metabolites such as 5-HETE have been implicated as
growth promoting factors for various human cancers (Avis et al,
1996; Ghosh and Myers, 1998; Ding et al, 1999a). Here, we demon-
strate that the resinous plant exsudate NDGA, a 5-lipoxygenase
inhibitor, markedly inhibits anchorage-independent growth of
human pancreatic and cervical cancer cells in serum as well as
growth of xenograft tumours established from these cells in athy-
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Figure 5 (A) Cytochalasin D activates of JNK1/2 in SW 850 and C4-I
cells: Top panel: SW 850 cells were incubated with various concentrations
of cytochalasin D (Cyto D) for 60 min as indicated. Control cells received
an equivalent amount of solvent. JNK activity was determined in JNK-im-
mune complex kinase assays using a GST-cJun fusion protein as substrate
as described in Materials and Methods. The position of the GST-cJun fusion
protein is indicated by an arrow. (B) NDGA induces activation of JNK1/2 in
SW 850 and C4-I cells. Top panel: Concentration dependence of NDGA-
induced JNK activation. C4-I cells were incubated with various concentra-
tions of NDGA for 60 min as indicated. Control cells received an equiva-
lent amount of solvent. Cells were further analysed by JNK1/2-immune
complex kinase assays using GST-cJun as substrate. Middle and bottom pa-
nels: SW 850 (left) and C4-I cells (right) were incubated with 25 mM
NDGA (N) or 1 mM mannitol (M) for 60 min or received an equivalent
amount of solvent (7). Cells were subsequently analysed by JNK-immune
complex kinase assays as described in Materials and Methods. The experi-
ments shown are representative of at least three independent experiments.
Results from a representative experiment were subjected to scanning den-
sitometry. The data are expressed as per cent of maximal GST-cJun phos-
phorylation obtained in response to 1 mM mannitol in both cell lines. (C)
Kinetics of NDGA-induced activation of JNK1/2. Top: Serum starved SW
850 cells were treated with 25 mM NDGA for various times as indicated
and JNK1/2-immune complex kinase assays were performed as described
in Materials and Methods. A typical result in SW 850 cells was subjected
to scanning densitometry. Data are expressed as per cent of maximal
JNK 1/2 activation obtained after 60 min of incubation.
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signaling pathways such as the activation of receptor tyrosine
kinases, PI3-kinase/p70
s6k or the ERK cascade demonstrating that
NDGA is not acting as a general kinase inhibitor in pancreatic
and cervical cancer cell lines. Many cancers have been shown to
lose growth control as a result of defects in cell cycle control.
Cyclin D1, which is crucial for promoting cell cycle progression,
is constitutively expressed in pancreatic (Kornmann et al, 1998),
but also in cervical cancer cells and could – at least in part –
be responsible for the transformed phenotype of these cells. Our
data demonstrate that NDGA selectively inhibits constitutive cyclin
D1 expression in both cancer cell lines providing a molecular
mechanism of its growth inhibitory properties.
Inhibition of cyclin D1 can lead to cell cycle arrest and under
certain circumstances to the induction of apoptosis (Tan et al,
2000). NDGA markedly induced apoptosis in SW 850 and C4-I
cells in vitro and also in xenograft tumours established in athymic
mice. This suggests that similar mechanisms mediate the effects of
NDGA in vitro and in vivo. Again, the induction of apoptosis by
NDGA was not due to inhibition of Ras-dependent survival path-
ways including the antiapoptotic kinase AKT. Instead, our data
suggest that NDGA induces anoikis by disrupting the ﬁlamentous
actin cytoskeleton in human pancreatic and cervical cancer cells.
The effect of NDGA on actin stress ﬁbers was comparable to that
of cytochalasin D. In contrast to cytochalasin D, the effect of
NDGA on the actin cytoskeleton appears to be cell type speciﬁc:
NDGA could affect actin stress ﬁbres in ﬁbroblasts (Hirata et al,
1984; Chong et al, 1987), but failed to do so in leukocytes (Shalit
et al, 1987) or keratinocytes (Coutant et al, 1997).
Anoikis is accompanied by induction of stress activated
protein kinases (Frisch et al, 1996; Khwaja and Downward,
1997). Indeed, cytochalasin D potently induced activation of
JNK1/2 in both cell lines. NDGA similarly activated JNK1/2
and p38
mapk but had no effect on ERK1/2 activation in SW
850 and C4-I cells. Again, this effect of NDGA is likely to be
cell type speciﬁc: No effect of NDGA on JNK activation could
be demonstrated in vascular smooth muscle cells (Madamanchi
et al, 1998), HeLa cells and HL 60 cells (Hii et al, 1998). There
is some controversy regarding the possible role of stress activated
protein kinases as mediators of apoptosis. For example, there is
evidence that these kinases can mediate apoptosis under certain
circumstances (Behrens et al, 1999; Tournier et al, 2000) includ-
ing anoikis (Frisch et al, 1996). However, it has been questioned
whether JNK activation occurring 30 min after suspending the
cells by trypsinisation can contribute to anoikis (Khwaja and
Downward, 1997). The sequence of events presented in this
manuscript is different: We show that disruption of the actin
cytoskeleton by NDGA is associated with activation of JNK
and p38
mapk and that both events precede cell detachment. The
early activation of JNKs and p38
mapk prior to cell detachment
could contribute to anoikis. Our ﬁnding that similar concentra-
tions of NDGA are required for disruption of actin stress ﬁbres,
JNK activation and the induction of apoptosis further supports
our conclusion that these events could be related. However,
the precise contribution of JNK1/2 and p38
mapk activation to
NDGA-induced cytoskeletal disruption and apoptosis requires
further examination.
NDGA has been widely used as a speciﬁc lipoxygenase inhibi-
tor. The precise relationship between the inhibitory effect of
NDGA on lipoxygenases and the signalling events induced by
NDGA described in this paper is not clear. Ding et al (1999a)
described an inhibitory effect of NDGA on basal and 5-HETE-
induced DNA synthesis in pancreatic cancer cells at concentra-
tions comparable to those used in our experiments. This could
suggest that some of the signalling events are related to the lipox-
ygenase inhibitory action of NDGA. However, the activation of
JNKs and p38
mapk in response to NDGA seems to be cell type
speciﬁc, whereas NDGA will inhibit lipoxygenases in virtually all
cells. Thus, either the consequences of lipoxygenase inhibition
are cell type speciﬁc or NDGA induces additional effects in a
cell-type speciﬁc manner which are independent from its lipoxy-
genase inhibitory actions. Therefore, given the activation of
multiple signalling events by NDGA, this compound should not
be used anymore as a ‘speciﬁc’ lipoxygenase inhibitor without
the examination of additional pathways.
The effect of NDGA on tumour growth observed in vivo was
moderate but there was no toxicity detectable in the animals at
the concentration used. The fact that NDGA seems to be effective
against diverse and often incurable tumour types suggests that a
more detailed analysis of the effects of NDGA on tumour growth
in vivo is urgently required. Moreover, NDGA could provide a lead
compound for the development of novel therapeutics in pancreatic
and cervical cancer.
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Figure 6 NDGA selectively stimulates p38
mapk activation in SW 850 and
C4-I cells. (A) Top: SW 850 and C4-I cells were incubated with 25 mM
NDGA (N) or 1 mM mannitol (M) for 60 min. Control cells received an
equivalent amount of solvent (7). Cells were further analysed by p38
mapk
immune complex kinase assays using a GST-ATF2 fusion protein as sub-
strate. (A) Bottom panels: Typical results of p38
mapk immune complex ki-
nase assays in SW 850 (left) and C4-I cells (right) were subjected to
scanning densitometry. Data are expressed as per cent of maximal GST-
ATF2 phosphorylation obtained in response to 1 mM mannitol. (B) Top
panel: Serum starved SW 850 cells were incubated with various concentra-
tions of NDGA for 60 min and further analysed by Western blotting using
a phosphospeciﬁc anti-p38
mapk antibody as described in Materials and
Methods. (B) Bottom panel: Serum starved C4-I cells were incubated with
25 mM NDGA for various times and further analysed by Western blotting
using a phosphospeciﬁc anti-p38
mapk antibody as described in Materials and
Methods.
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